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Abstract
Background: Anthracycline-based adjuvant chemotherapy improves survival in patients with high-risk node-negative
breast cancer (BC). In this setting, prognostic factors predicting for treatment failure might help selecting among the
different available cytotoxic combinations.
Methods: Between 1998 and 2008, 757 consecutive patients with node-negative BC treated in our institution
with adjuvant FEC (5FU, epirubicin, cyclophosphamide) chemotherapy were identified. Data collection included
demographic, clinico-pathological characteristics and treatment information. Molecular subtypes were derived
from estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2)
status and Scarff-Bloom-Richardson (SBR) grade. Disease-free survival (DFS), distant disease-free survival (DDFS)
and overall survival (OS) were estimated using the Kaplan-Meier Method, and prognostic factors were examined by
multivariate Cox analysis.
Results: After a median follow-up of 70 months, the 5-year DFS, DDFS and OS were 90.6 % (95 % confidence interval
(CI): 88.2–93.1), 92.8 % (95 % CI: 90.7–95) and 95.1 % (95 % CI, 93.3–96.9), respectively. In the multivariate analysis
including classical clinico-pathological parameters, only grade 3 maintained a significant and independent adverse
prognostic impact. In an alternative multivariate model where ER, PR and grade were replaced by molecular subtypes,
only luminal B/HER2-negative and triple-negative subtypes were associated with reduced DFS and DDFS.
Conclusions: Node-negative BC patients receiving adjuvant FEC regimen have a favorable outcome. Luminal
B/HER2-negative and triple-negative subtypes identify patients with a higher risk of treatment failure, which might
warrant more aggressive systemic treatment.
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Background
With more than 1.3 million of new cases annually and
nearly 465,000 deaths, breast cancer (BC) is still the
leading cause of cancer mortality among females in the
world. In France, its incidence has been rising during
the last 25 years and 53,000 new cases of BC were diag-
nosed in 2011. Adjuvant chemotherapy improves survival
in early BC and is considered as one of the most signifi-
cant therapeutic achievements in this disease during
the last decades [1]. Initially, polychemotherapy, notably
cyclophosphamide-methotrexate-5FU (CMF) regimen,
was shown to significantly decrease relapses and deaths
over monochemotherapy or no post-operative treatment
at all [2, 3]. A few years later, anthracycline-based regi-
mens were shown to further improve outcome over CMF,
these effects being regarded as largely independent of
main tumor characteristics such as estrogen receptor (ER)
status, lymph node status and associated endocrine ther-
apy [1]. Therefore, at the end of 90’s, cyclophosphamide-
epirubicin-5FU (FEC) regimen became the reference
combination in France for adjuvant chemotherapy in
early BC, epirubicin 100 mg/m2 being shown as more
effective than 50 mg/m2 in a comparative randomized
trial [4]. More recently, taxanes were incorporated to
adjuvant anthracycline-based chemotherapy, with demon-
strated benefits in disease-free survival (DFS) and overall
survival (OS) when compared to anthracycline-based
combinations in various comparative randomized trials
[5, 6] and meta-analysis [7].
Most of the above described results were obtained
from clinical trials enrolling essentially node-positive BC
patients, but several studies also demonstrated a benefit
for adjuvant chemotherapy in patients with high-risk,
node-negative BC [8, 9], which was clearly confirmed by
meta-analyses [3, 10]. When focusing specifically on
anthracyline/taxane-based combinations, most of ran-
domized trials enrolled only node-positive BC, while
only few of them also included a limited number of
node-negative BC. In fact, only two randomized phase
III trials evaluating concomitant or sequential anthracy-
line/taxane-based combinations in a pure population of
node-negative BC were recently reported [11, 12], both
showing a benefit in DFS, but no clear superiority in OS.
Thus, regarding to the significant increase in costs and
acute toxicities, the use of these anthracyline/taxane-based
regimens in node-negative BC remains controversial.
Here, we have conducted a retrospective analysis of
a large single-center cohort of patients with high-risk
node-negative BC treated with adjuvant FEC chemo-
therapy. Our primary objective was to identify prognos-
tic factors for DFS, which might help better defining
node-negative BC patients candidate to the most aggres-
sive and costly anthracycline/taxane combinations. Spe-
cifically, we have examined the prognostic impact of
clinico-pathological parameters classically used to indi-
cate adjuvant chemotherapy and that of immuno-
histochemically (IHC)-defined molecular subtypes of
BC. Our secondary objectives were to describe OS and
distant-disease free survival (DDFS) in this popula-
tion. An additional secondary objective was to derive
prognostic factors for DDFS.
Methods
Patient population
The study population was identified from our prospect-
ively maintained institutional database. This institutional
clinical data base on breast cancer is operated by DATA
MANAGEMENT AND ANALYSIS CENTER (DMAC),
approved for its data management skills as data processing
centers by INCa (French National Institute for Cancer) in
2007. DMAC is also ISO 9001 certified. Standard operat-
ing procedures are applied to collect, check and use data
in the quality management system framework. Data are
entered (source is medical records) in an ORACLE
database by Clinical Research Assistant.
The following inclusion criteria were used : all consecu-
tive women diagnosed with invasive BC over a 11-year
period between January 1998 and December 2008, treated
with primary surgery (tumor resection and axillary staging
by sentinel lymph node biopsy (SLNB) and/or axillary
lymph node dissection (ALND)), pathologically node-
negative (pN0) and treated with adjuvant FEC chemother-
apy (at least 4 cycles of FEC50,75 or 100). Exclusion
criteria were metastatic disease, node-positive or nodal
status unknown or patient receiving neo-adjuvant treat-
ment. A flow diagram of the population selection steps is
provided in Fig. 1.
The study was approved by the Institut Paoli-
Calmettes (IPC) Institutional Review Board (IRB, Comité
d’Orientation Stratégique, COS). According to national
guidelines, the IRB considered that there was no need
for collecting informed consent for this kind of database
study. Data were analyzed after all patient information
have been fully anonymized.
Clinical and biological variables
The following patient’s baseline characteristics were
collected: age, type of surgery and axillary lymph node
staging, pathological tumor size, histologic subtype, Scarf-
Bloom-Richardson (SBR) grade (tubule formation, nuclear
pleomorphism and mitotic count), peritumoral vascular
invasion (PVI), IHC status for standard prognostic bio-
markers : estrogen receptor (ER), progesterone receptor
(PR) and human epidermal growth factor receptor 2
(HER2). For ER and PR, cases with 10 % or more positive
staining were considered as positive. Hormone receptors
(HoR) were considered as positive when ER and/or PR
were positive. For HER2, the cases with 3+ staining by
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IHC and/or amplification by in situ hybridization method
were considered as positive.
Five molecular subtypes were defined according to
clinico-pathologic criteria. Because information on Ki-67
was only partially available, we used SBR grade to
capture cell proliferation, as previously described [13].
The following definitions were used: triple-negative
(HoR-negative/HER2-negative/all grades), HER2-positive
(HoR-negative/HER2-positive/all grades), luminal (HoR-
positive), which was divided in luminal A (HoR-positive/
HER2-negative/SBR grade 1 or 2), luminal B/HER2-




Adjuvant chemotherapy was indicated for pN0 patients
in case of high-risk features, defined as: pathological
tumor size ≥15 mm, HoR-negative tumors, SBR grade 2
or 3, PVI, or age <40. FEC regimen was started within
12 weeks of surgery and included fluorouracil 500 mg/
m2, epirubicin 50-75-100 mg/m2, cyclophosphamide
500 mg/m2, administered every 21 days for 4–6 cycles.
Following completion of chemotherapy, patients were
given adjuvant radiotherapy when appropriate and hor-
monal therapy in case of HoR-positivity (tamoxifen or
aromatase inhibitors). From 2005, patients with HER2-
positive BC were offered adjuvant trastuzumab after
completion of radiotherapy.
Statistical analyses
The primary objective of this study was to identify prog-
nostic factors for disease-free survival (DFS). Secondary
objectives included description of distant DFS (DDFS)
and overall survival (OS), as well as an exploratory ana-
lysis of prognostic factors for DDFS. Due to the low
number of death events, no prognostic analysis was con-
ducted for OS. DFS was defined as the time from diag-
nosis to local, node, contralateral or distant relapse or
death from any cause. DDFS was defined as the time
from diagnosis to distant relapse or death from any
cause. OS was defined as the time from diagnosis to
death from any cause. For patients who remained alive
and disease-free, data were censored at the date of the
last follow up.
Descriptive statistics were used to describe the categor-
ical (counts and frequency) and continuous (median and
ranges) variables. DFS, DDFS and OS rates were estimated
using the Kaplan–Meier method and compared with the
log-rank test. Multivariate analysis was conducted using
Cox’s proportional hazard regression model. All statistical
tests were two-sided. The level of statistical significance
was set at a P-value of 0.05. Statistical analyses were car-
ried out with the R software version 2.15.2. We followed
the “Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE)” guidelines [14].
Results
Patient’s characteristics
A total of 757 patients were identified (Fig. 1), the char-
acteristics of which are presented in Table 1. Median age
was 53 years (range, 24–79), more than half of patients
had pT1 tumor (52 %), and most of tumors were HoR-
positive (72 %), ductal histologic type (79 %), and 1 or 2
SBR grade (62 %). HER2 status was available for 80 % of
cases and was positive in 16 % of those cases. Most of
patients had breast-conserving surgery (73 %), received
adjuvant radiation therapy (90 %) and hormonal therapy
(70 %). Almost all patients received FEC100 regimen
(94 %), FEC75 or FEC50 being usually administered if
age was more than 70. Of note, 41 % of patients with
HER2-positive documented BC received trastuzumab
after chemotherapy and radiotherapy completion, corre-
sponding to 85 % of HER2-positive cases diagnosed after
September 2005, when trastuzumab became available in
the adjuvant setting in France, but less than 5 % of those
diagnosed before this date. Reasons for not receiving
Fig. 1 Flow diagram
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trastuzumab after September 2005 were: heart failure
(n = 1), patient refusal (n = 1), discordant or equivocal
pathological result (n = 2), unknown (n = 3).
Outcome
The estimated median follow-up was 70 months (95 %
confidence interval (CI): 63.5–75.0). Sixty-nine DFS
events, including 38 distant metastases and 39 deaths
were observed. The estimated 5-year DFS, primary end-
point of this study, was 90.6 % (95 % CI: 88.2–93.1;
Fig. 2A). Regarding the secondary outcome endpoints, the
estimated 5-year DDFS was 92.8 % (95 % CI: 90.7–95;
Fig. 2B) and 5-year OS was 95.1 % (95 % CI: 93.3–96.9;
Fig. 2C).
Clinico-pathological predictors of DFS
In the univariate analysis, the following parameters were
associated with a reduced DFS (Table 2): SBR grade 3
(hazard ratio (HR) =1.8, 95 % CI [1.1–2.9], p = 0.0138),
PVI (HR = 2.3, 95 % CI [1.4–3.7], p = 0.0007), and IHC
subtypes (p = 0.0006). As for the latter, luminal B/HER2-
negative (HR = 4.3, 95 % CI [2–9.1]) and triple-negative
(HR = 2.6, 95 % CI [1.2–5.5]) subtypes were associated
with an adverse outcome (Fig. 3). Of note, pathological
tumor size, HER2 and ER status were not prognostic in
this treated population. In the multivariate analysis, only
grade 3 (HR = 2.8, 95 % CI [1.4–5.4], p = 0.0027) retained
an independent prognostic value (Table 3). In an alterna-
tive multivariate Cox model in which ER, PR and grade
were replaced by IHC subtypes, only luminal B/HER2-
negative (HR = 4.25, 95 % CI [1.9–9.15], p = 0.0002) and
triple-negative (HR = 2.5, 95 % CI [1.15–5.4], p = 0.0201)
subtypes were independently associated with an adverse
outcome (Table 3).
Since a large part of patients with documented HER2-
positive BC received adjuvant trastuzumab after September
2005, we performed an exploratory analysis focused on
patients treated before this period (n = 460). In this subset
of patients, HER2 was still not significantly associated with
DFS, and the same variables (grade 3, PVI, IHC subtypes)
were found to be predictive in the univariate analysis (See
Additional file 1). In the multivariate analysis, SBR grade 3
remained significantly associated with poor DFS, while a
similar trend was observed for PVI (See Additional file 2).
Once again, IHC subtypes (Luminal B/HER2-negative and,
with borderline significance, triple-negative), instead of
Table 1 Patient characteristics
Age (Years) Median [range] 53 (24–79)
<35 (%) 30 (4 %)
≥70 (%) 43 (6 %)
Type of surgery Lumpectomy 552 (73 %)
Complete mastectomy 205 (27 %)
Axillary management Lymph node dissection 395 (52 %)
Sentinel lymph node biopsy 362 (48 %)
Histological type Invasive ductal carcinoma 599 (79 %)
Invasive lobular carcinoma 66 (9 %)
Other invasive carcinoma 92 (12 %)
Pathological tumor
size (pT)
pT1a-b 63 (8 %)
pT1c 329 (44 %)
pT2 320 (43 %)
pT3-T4 36 (5 %)
SBR grade 1 132 (18 %)
2 331 (44 %)




No 558 (76 %)
Yes 174 (24 %)
NA 25
Hormone receptors
ER Negative 229 (31 %)
Positive 506 (69 %)
NA 32
PR Negative 287 (39 %)
positive 441 (61 %)
NA 29
ER or PR Negative 208 (28 %)
Positive 527 (72 %)
NA 22
HER2 status Positive 96 (16 %)
Negative 508 (84 %)
NA 153
IHC subtypes Triple-negative 127 (21 %)
Luminal A 290 (49 %)
Luminal B/HER2-negative 82 (14 %)
Luminal B/HER2-positve 58 (10 %)
HER2 37 (6 %)
NA 163
Adjuvant chemotherapy FEC 100 716 (94 %)
FEC 50/75 41 (6 %)
Adjuvant hormone therapy Yes 532 (70 %)
No 224 (30 %)
NA 1
Table 1 Patient characteristics (Continued)
Adjuvant radiation therapy Yes 681 (90 %)
No 76 (10 %)
Adjuvant trastuzumab
(HER2-positive)
Yes 40 (41 %)
No 56 (59 %)
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Fig. 2 Disease-free survival (a), distant disease-free survival (b) and overall survival (c) in high-risk node-negative early breast cancer patients receiving
adjuvant FEC
Table 2 Prognostic factors for disease-free survival (DFS): univariate analysis
N 5-Year DFS (%) (95 % CI) HR (95 % CI) p-valuea
Age
< 35 30 82.6 [68.2–100] 1
≥ 35 726 90.9 [88.5–93.4] 0.5 [0.2–1.3] 0.136
SBR Grade
1–2 462 93.2 [90.5–95.9] 1
3 285 86 [81.4–91] 1.8 [1.1–2.9] 0.0138
Pathological tumor size
pT1 391 91.2 [87.9–94.5] 1
pT2 320 90 [86.2–94] 1.1 [0.7–1.8]
pT3-T4 36 88.2 [78–99.8] 1.1 [0.4–3] 0.9514
PVI
No 558 92.3 [89.7–95] 1
Yes 178 85 [79–91.4] 2.3 [1.4–3.7] 0.0007
Hormone receptors
Negative 208 86.8 [81.6–92.4] 1
Positive 526 92.5 [89.9–95.2] 0.7 [0.4–1.1] 0.1059
HER2
Negative 507 91 [88–94.1] 1
Positive 96 95.7 [91–100] 0.6 [0.2–1.6] 0.376
IHC subtypes
Luminal A 289 95.1 [92.1–98.2] 1
Luminal B/HER2-negative 82 80.1 [69.8–92] 4.3 [2–9.1]
Luminal B/HER2-positive 58 100 [100–100] 0.7 [0.2–3.3]
HER2 37 89 [77.6–100] 1.8 [0.5–6.2]
Triple-negative 127 87.6 [80.7–95] 2.6 [1.2–5.5] 0.0006
HR hazard ratio, PVI peritumor vascular invasion
aunadjusted log-rank test
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SBR grade, HER2 and HR, were independently associated
with DFS (Additional file 2: Table S2).
Clinico-pathological predictors of DDFS
When looking at variables associated with DDFS, SBR
grade 3 (HR = 2.8, 95 % CI [1.6–4.9], p = 0.0002), PVI
(HR = 2.2, 95 % CI [1.3–4], p = 0.0042), lack of hormone
receptor expression (HR = 0.6, 95 % CI [0.3–1], p = 0.049),
and luminal B/HER2-negative (HR = 4.6, 95 % CI
[1.8–11.7]) and triple-negative (HR = 3.3, 95 % CI
[1.3–8.2]) IHC subtypes (p = 0.0059) were associated
with reduced DDFS in the univariate analysis (Table 4). In
the multivariate analysis, only grade (HR = 3.4 95 % CI
[1.5–7.6], p = 0.0027) had an independent value (Table 5).
Again, when replacing hormone receptor and grade by
IHC subtypes, only the latter had an independent
prognostic value, with luminal B/HER2-negative and
triple-negative subtypes being associated with an adverse
outcome (Table 5).
Discussion
In this paper, we have examined the clinical outcome of
a large, single-centre, retrospective cohort of patients
with high-risk node-negative early BC receiving post-
operative FEC-based chemotherapy. With a 5-year DFS
of more than 90 %, and a 5-year OS of more than 95 %,
overall prognosis was considered to be excellent, but
some subsets of patients were identified as displaying a
less favorable outcome. Namely, the presence of a SBR
grade 3 still predicted for a higher risk of relapse. A
similar independent dismal prognosis was identified for
luminal B/HER2-negative and triple-negative subtypes,
suggesting that these patients might be the best candidate
to more aggressive adjuvant chemotherapy, including the
more aggressive and costly anthracycline and taxane-
based combination.
Histologic grade is a semi-quantitative estimation of
the degree of tubular or gland formation, nuclear
polymorphism and mitotic count [15], the independent
prognostic impact of which was recurrently demonstrated
in various settings [16], including node-negative or
node-positive disease [17]. Accordingly, high grade
has been considered as a major determinant for adju-
vant chemotherapy decision, which is related at least
partially to its dependency on cell proliferation and
mitosis. Here, we have shown that SBR grade still
retains an independent adverse prognostic value, in
the context of node-negative BC patients receiving
anthracycline-based adjuvant chemotherapy. Thus,
even though it does not seem to predict a specific
sensitivity to a particular class of drug, it may indi-
cate a subset of BC patients in which adding taxanes
Fig. 3 Disease-free survival according to immunohistochemical subtypes
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to anthracylines may be of interest in spite of the
absence of lymph node invasion.
PVI was shown to be an adverse prognostic parameter
in early BC, notably in node-negative BC, where it has
been considered as a surrogate for occult vascular dissem-
ination [18]. Its prognostic value has been also described
within the different breast cancer subtypes [19, 20]. In our
study, whereas it was consistently associated with DFS
and DDFS, it was not retained as an independent prognos-
ticator in all multivariate models tested. That suggests
that, in the context anthracycline-based adjuvant CT, the
unfavorable prognostic impact of PVI is not as important
as proliferation status and subtypes. This lack of prognos-
tic value in multivariate analysis including breast cancer
subtypes could also be explained by the fact that PVI was
recently shown to correlate with the luminal B/HER2-
negative subtype [21].
Of note, age and pathological tumor size were not
associated with survival, although being classical
prognosticators currently used to recommend adjuvant
chemotherapy. Thus, following anthracycline-based
adjuvant chemotherapy, prognosis and therefore the
potential need for taxane-based treatment, may more
result from biological rather than from pure clinical
features.
Notably, the lack of hormone receptors and HER2
overexpression were not individually associated with a
significantly higher risk of relapse. This may be related
to the classically documented efficacy of anthracycline-
based adjuvant chemotherapy in HR-negative tumors
[1, 3]. An explanation for the relative favorable outcome
of patients with HER2 overexpression may be that a
significant fraction of those patients received, after
completion of chemotherapy and radiotherapy, adjuvant
trastuzumab, the impact of which was largely demon-
strated during the last 10 years [22, 23]. However, a
sensitivity analysis focused on patients treated before 2005
September (date of initiation of adjuvant trastuzumab in
Table 3 Prognostic factors for disease-free survival: multivariate analysis
Model 1 (N = 570) Model 2 (N = 575)
HR (95 % CI) p-valuea HR (95 % CI) p-valuea
Age
< 35 1 1
≥ 35 0.5 [0.1–2.3] 0.581 0.5 [0.1–.396] 0.440
SBR Grade
1–2 1 NA
3 2.8 [1.4–5.4] 0.0027 NA
Pathological tumor size
pT1 1 1
pT2 0.9 [0.5–1.7] 0.897 0.9 [0.5–1.7] 0.916
pT3-T4 0.4 [0.05–3.3] 0.431 0.4 [0.06–3.4] 0.447
PVI
No 1 1
Yes 1.5 [0.8–3.0] 0.175 1.3 [0.7–2.6] 0.357
Hormone receptors
Negative 1 NA
Positive 1.0 [0.5–2.2] 0.818 NA
HER2
Positive 1 NA
Negative 0.5 [0.2–1.4] 0.239 NA
IHC subtypes
Luminal A NA 1
Luminal B/HER2-negative NA 4.2 [1.9–9.1] 0.0002
Luminal B/HER2-positive NA 0.7 [0.1–3.4] 0.721
HER2 NA 1.76 [0.4–6.1] 0.38
Triple-negative NA 2.5 [1.1–5.4] 0.0201
HR hazard ratio, PVI peritumor vascular invasion
aWald test
Rahal et al. BMC Cancer  (2015) 15:697 Page 7 of 11
HER2-positive BC at our institution) did not show a
significant adverse impact of HER2-overexpression in this
population. An alternative hypothesis could be the sus-
pected link between HER2 amplification and sensitivity to
anthracycline-based regimen [24, 25], possibly due to
frequent co-amplification or deletion of TOP2A, the gene
encoding topoisomerase IIα protein, which is a supposed
intracellular target for anthracyclines [26].
Results from transcriptomic studies have shown that
BC is an heterogeneous disease that can be divided in at
least 5 molecular subtypes (basal-like, HER2-enriched,
luminal A, luminal B and normal-like) with specific gene
expression patterns, distinct clinical outcome and sensi-
tivity to systemic treatments [27]. Accordingly, it has
been hypothesized that identifying these BC subtypes in
the clinic could help better tailoring individual thera-
peutic choices. Since molecular subtypes are only
precisely identified by sophisticated gene expression
profiling technologies not readily applicable to clinical
samples in routine, it has become increasingly popular
to approximate these subtypes using IHC evaluation of
ER, PR and HER2 expression, combined to a surrogate
of the proliferation status such as Ki-67 expression or
grade. The main objective of this subtype-based classifi-
cation has been to identify patients with low or no tumor
burden in the axillary lymph node and a relatively indolent
disease, who could be spared from adjuvant cytotoxic
treatment [28]. Thus, according to this classification, most
of luminal A tumors need endocrine but not cytotoxic
treatment, whereas adjuvant chemotherapy is recom-
mended in tumors identified as triple-negative, luminal B
(followed by endocrine treatment), and HER2 (with tras-
tuzumab). In this study, we have used IHC subtypes to
identify patients with node-negative BC receiving adjuvant
FEC who may have still a significant residual risk of re-
lapse. Triple-negative and luminal-B/HER2-negative sub-
types displayed the worst outcome, including a distant
relapse risk which was higher than 10 % in both cases,
Table 4 Prognostic factors for distant disease-free survival: univariate analysis
N 5-Year DDFS (%) (95 % CI) HR (95 % CI) p-valuea
Age
< 35 30 82.6 [68.2–100] 1
≥ 35 726 93.3 [91.2–95.4] 0.5 [0.2–1.3] 0.1223
SBR Grade
1–2 462 96 [94–98] 1
3 285 87.4 [82.9–92.1] 2.8 [1.6–4.9] 0.0002
Pathological tumor size
pT1 391 93.6 [90.9–96.5] 1
pT2 320 92.3 [88.9–95.7] 1.2 [0.7–2]
pT3-T4 36 88.2 [78–99.8] 1.6 [0.6–4.7] 0.6395
PVI
No 558 94.2 [92–96.5] 1
Yes 178 88.8 [83.5–94.5] 2.2 [1.3–4] 0.0042
Hormone receptors
Negative 208 88 [83–93.4] 1
Positive 526 94.7 [92.5–96.9] 0.6 [0.3–1] 0.049
HER2
Negative 507 93.2 [90.5–95.9] 1
Positive 96 95.7 [91–100] 0.9 [0.3–2.2] 0.7719
IHC subtypes
Luminal A 289 96.8 [94.5–99.2] 1
Luminal B/HER2-negative 82 85.5 [76.3–95.8] 4.6 [1.8–11.7]
Luminal B/HER2-positive 58 100 [100–100] 1.2 [0.2–5.5]
HER2 37 89 [77.6–100] 2.9 [0.8–11.1]
Triple-negative 127 89 [82.5–96] 3.3 [1.3–8.2] 0.0059
HR hazard ratio, PVI peritumor vascular invasion
aunadjusted log-rank test
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theoretically justifying a more aggressive systemic
treatment. Triple-negative status is a very well-known
poor prognostic factor in early BC and some retro-
spective analyses of randomized studies have shown
that this subset of tumors may derive a pronounced
benefit from taxane addition, including node-negative
BC [29–31]. However, the triple-negative subtype has
been shown to be heterogeneous at the molecular
level, including various subtypes with distinct clinical
behavior and phenotype of drug sensitivity [32].
Specifically, recent data have identified a favorable
prognosis in triple-negative BC receiving anthracyline-
based adjuvant chemotherapy and displaying a high
level of lymphocytic infiltration [33, 34].
Notably and surprisingly, the luminal B/HER2-negative
subtype was found to be even more aggressive, with a
5-year risk of relapse of 20 %, including a risk of
distant relapse of nearly 15 %. The aggressive clinical
behavior of Luminal B tumors is well known and
their prognosis has been considered as similar to that
of HER2-enriched and basal-like groups [35]. However,
while triple-negative and Luminal B/HER2-positive
tumors might derive higher benefits from anthracyclines
and/or anti-HER2 adjuvant treatment, some Luminal B/
HER2-negative could be sub-optimally treated with
anthracycline-only regimen. Thus, these results suggest
that these tumors should also be candidate to more ag-
gressive chemotherapy with addition of taxanes to
anthracycline-based combination. Of note, in the French
PACS 01 study, which compared in node-positive BC
treated in the adjuvant setting 6 cycles of FEC100 versus
3 cycles FEC100 followed by 3 cycles of docetaxel, luminal
B tumors were shown to derive the highest benefit from
taxane addition [36].
Even though they were not found to display a signifi-
cantly higher risk of relapse in our study (which could be
Table 5 Prognostic factors for distant disease-free survival: multivariate analysis
Model 1 (N = 570) Model 2 (N = 575)
HR (95 % CI) p-valuea HR (95 % CI) p-valuea
Age
< 35 1 1
≥ 35 0.4 [0.1–2.1] 0.344 0.4 [0.09–1.8] 0.251
SBR Grade
1–2 1 NA
3 3.4 [1.5–7.6] 0.0027 NA
Pathological tumor size
pT1 1 1
pT2 1.0 [0.5–2.0] 0.932 1.0 [0.5–2.1] 0.847
pT3-T4 0.7 [0.09–5.3] 0.733 0.7 [0.09–5.5] 0.763
PVI
No 1 1
Yes 1.7 [0.8–3.6] 0.155 1.5 [0.7–3.2] 0.275
Hormone receptors
Negative 1 NA
Positive 0.9 [0.4–2.0] 0.865 NA
HER2
Positive 1 NA
Negative 0.7 [0.2–2.0] 0.605 NA
IHC subtypes
Luminal A NA 1
Luminal B-HER2–negative NA 4.4 [1.7–11.5] 0.0018
Luminal B-HER2-positive NA 1.2 [0.2–5.9] 0.775
HER2 NA 2.8 [0.7–10.9] 0.118
Triple-negative NA 3.4 [1.3–8.7] 0.0074
HR hazard ratio, PVI peritumor vascular invasion
aWald test
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due to the relatively limited sample size of this subgroup),
HER2-positive subtypes are also pragmatic candidates to
taxane, since it is a way to earlier initiate trastuzumab,
either after a limited anthracycline-based sequence or at
the beginning of chemotherapy in the context of
anthracycline-free combinations. Indeed, early initiation of
trastuzumab has been associated with better outcome,
while reducing anthracycline exposure may limit cardiac
toxicity [37]. Finally, with a risk of distant relapse of less
than 4 %, luminal A BC had an excellent outcome and the
most relevant question in this subset of patients, sensitive
to hormone therapy, is whether these patients do actually
need any cytotoxic treatment. Various multigenic signa-
tures are now available that are specifically addressing this
issue [38, 39] and the prospective validation of some of
them is currently under analysis [40, 41].
This study has several strengths lying in the number
of samples analyzed (more than 750), the duration of the
follow-up (nearly 8 years in median) and the high-
quality of data collected by a certified Data Management
and Analysis Center. Weaknesses include its retrospect-
ive monocentric, non-randomized and non-comparative
nature, the lack of central and ad hoc review of bio-
logical variables, the relatively high number of missing
data for analysis of molecular subtypes (n = 163), notably
the number of missing HER2 status, the discussable ap-
proximation of luminal A/B distinction based on grade
only, rather than on Ki67 and the low number of death
events, precluding the identification of prognostic factors
for OS. Another potential bias may be the definition of
high-risk features used to indicate adjuvant chemotherapy
during this period (pathological tumor size ≥15 mm, HoR-
negative tumors, SBR grade 2 or 3, PVI, or age <40),
which is not the same as currently used. Finally, the rela-
tively low number of HER2-positive patients receiving
trastuzumab (49 %) may also affect the clinical relevance
of our results in routine practice.
In spite of the above-mentioned limitations, our main
result suggests that triple-negative and luminal-B/HER2-
negative subtypes have a significant residual risk of
relapse following FEC adjuvant chemotherapy. This may
support the use of taxanes in these subsets of patients,
even when node-negative, but additional researches are
warranted in order to better predict a specific thera-
peutic benefit of this class of drugs according to the
tumor features.
Conclusions
In conclusion, our results suggest a relative favorable
outcome in node-negative BC treated with FEC-based
adjuvant chemotherapy. However, SBR grade 3 or triple-
negative and luminal-B/HER2-negative subtypes may
indicate which patients are candidates to anthracyline
and taxane-based combinations.
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